{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:57:48Z","timestamp":1790229468052,"version":"4.1.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Myasthenia gravis (MG) is an autoimmune disorder involving complex interactions between genetic and environmental factors. Genome-wide association studies (GWAS), transcriptome-wide association studies (TWAS), and other methods have identified multiple novel susceptibility loci and genes, providing crucial insights into the genetic etiology of MG. Moreover, the pivotal roles of epigenetic mechanisms, such as DNA methylation, histone modifications, and non-coding RNAs, in the pathogenesis of MG are gradually being unveiled. This review comprehensively summarizes the latest advances in MG genetic research, focusing on the discovery and validation of susceptibility genes, genetic heterogeneity and subtype-specific genetic factors, gene\u2013environment interactions, epigenetic mechanisms, and progress in genetics-based diagnostic and prognostic biomarkers.<\/jats:p>","DOI":"10.3389\/fmed.2024.1508422","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T01:55:50Z","timestamp":1736214950000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Advances in the genetics of myasthenia gravis: insights from cutting-edge neuroscience research"],"prefix":"10.3389","volume":"11","author":[{"given":"Zheng","family":"Yixian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Hai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Xiuying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jichun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","article-title":"The epidemiology of myasthenia gravis","volume":"14","author":"Bubuioc","year":"2021","journal-title":"J Med Life"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/B978-0-323-98818-6.00010-8","article-title":"Myasthenia gravis and congenital myasthenic syndromes","volume":"195","author":"Gilhus","year":"2023","journal-title":"Handb Clin Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/B978-0-12-823912-4.00026-8","article-title":"Myasthenia gravis-pathophysiology, diagnosis, and treatment","volume":"200","author":"Tannemaat","year":"2024","journal-title":"Handb Clin Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.36185\/2532-1900-038","article-title":"Myasthenia gravis: MuSK MG, late-onset MG and ocular MG","volume":"39","author":"Deymeer","year":"2020","journal-title":"Acta Myol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/WCO.0000000000000596","article-title":"Myasthenia gravis: from autoantibodies to therapy","volume":"31","author":"Mantegazza","year":"2018","journal-title":"Curr Opin Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1038\/s41467-022-31951-8","article-title":"Myasthenia gravis-specific aberrant neuromuscular gene expression by medullary thymic epithelial cells in thymoma","volume":"13","author":"Yasumizu","year":"2022","journal-title":"Nat Commun"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e2206754119","DOI":"10.1073\/pnas.2206754119","article-title":"Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study","volume":"119","author":"Chia","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.2174\/1567202620666230703122140","article-title":"Myasthenia gravis and ischemic stroke: a bidirectional Mendelian randomization study","volume":"20","author":"Liu","year":"2023","journal-title":"Curr Neurovasc Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e37909","DOI":"10.1136\/bmjopen-2020-037909","article-title":"Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America","volume":"10","author":"Green","year":"2020","journal-title":"BMJ Open"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1136\/jmedgenet-2021-107953","article-title":"Myasthenia gravis genome-wide association study implicates AGRN as a risk locus","volume":"59","author":"Topaloudi","year":"2022","journal-title":"J Med Genet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s10072-023-07163-3","article-title":"Myasthenia gravis and five autoimmune diseases: a bidirectional Mendelian randomization study","volume":"45","author":"Li","year":"2024","journal-title":"Neurol Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12967-024-04994-2","article-title":"Integrative multi-omics analysis identifies genetically supported druggable targets and immune cell specificity for myasthenia gravis","volume":"22","author":"Li","year":"2024","journal-title":"J Transl Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1186\/s12967-023-04421-y","article-title":"Peripheral immune landscape for hypercytokinemia in myasthenic crisis utilizing single-cell transcriptomics","volume":"21","author":"Zhong","year":"2023","journal-title":"J Transl Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.21037\/tp-22-593","article-title":"Single-cell transcriptomics and network pharmacology reveal therapeutic targets of Jianpi Yiqi Bugan Yishen decoction in immune cell subsets of children with myasthenia gravis","volume":"11","author":"Liu","year":"2022","journal-title":"Transl Pediatr"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s44321-024-00043-z","article-title":"B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis","volume":"16","author":"Tian","year":"2024","journal-title":"EMBO Mol Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40246-024-00607-7","article-title":"Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis","volume":"18","author":"Ouyang","year":"2024","journal-title":"Hum Genomics"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00228-019-02803-0","article-title":"Multiple genetic factors affecting the pharmacokinetic and pharmacodynamic processes of tacrolimus in Chinese myasthenia gravis patients","volume":"76","author":"Meng","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/s41598-021-81962-6","article-title":"Construction of a TF-miRNA-gene feed-forward loop network predicts biomarkers and potential drugs for myasthenia gravis","volume":"11","author":"Bo","year":"2021","journal-title":"Sci Rep"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3892\/ijmm.2017.2853","article-title":"Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis","volume":"39","author":"Cao","year":"2017","journal-title":"Int J Mol Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"667336","DOI":"10.3389\/fimmu.2021.667336","article-title":"Next-generation sequencing identifies extended HLA class I and II haplotypes associated with early-onset and late-onset myasthenia gravis in Italian, Norwegian, and Swedish populations","volume":"12","author":"Creary","year":"2021","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1007\/s10072-022-06102-y","article-title":"HLA-DQB1*05:02, *05:03, and *03:01 alleles as risk factors for myasthenia gravis in a Spanish cohort","volume":"43","author":"Salvado","year":"2022","journal-title":"Neurol Sci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3389\/fimmu.2020.00707","article-title":"Muscle-specific kinase myasthenia gravis","volume":"11","author":"Borges","year":"2020","journal-title":"Front Immunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.3760\/cma.j.cn112137-20210904-02019","article-title":"Analysis of clinical characteristics and related genetic variation of juvenile myasthenia gravis","volume":"102","author":"Yang","year":"2022","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s13760-023-02370-3","article-title":"Genetic, serological and clinical evaluation of childhood myasthenia syndromes- single center subgroup analysis experience in Turkey","volume":"123","author":"\u00d6zsoy","year":"2023","journal-title":"Acta Neurol Belg"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1136\/bmj.2.5308.807","article-title":"Role of the thymus and related organs in immunity","volume":"2","author":"Burnet","year":"1962","journal-title":"Br Med J"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12974-024-03095-7","article-title":"Thymic gene expression analysis reveals a potential link between HIF-1A and Th17\/Treg imbalance in thymoma associated myasthenia gravis","volume":"21","author":"Altinonder","year":"2024","journal-title":"J Neuroinflammation"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"926516","DOI":"10.3389\/fimmu.2022.926516","article-title":"Key factors for Thymic function and development","volume":"13","author":"Shichkin","year":"2022","journal-title":"Front Immunol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"577950","DOI":"10.1016\/j.jneuroim.2022.577950","article-title":"Immunodeficiency in patients with thymoma-associated myasthenia gravis","volume":"371","author":"Ishizuchi","year":"2022","journal-title":"J Neuroimmunol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"577978","DOI":"10.1016\/j.jneuroim.2022.577978","article-title":"Enrichment of serum IgG4 in MuSK myasthenia gravis patients","volume":"373","author":"Vergoossen","year":"2022","journal-title":"J Neuroimmunol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e646","DOI":"10.1212\/NXI.0000000000000646","article-title":"Treating muscle-specific kinase myasthenia gravis from the inside out","volume":"7","author":"Huijbers","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ncl.2020.03.005","article-title":"Therapeutic and diagnostic challenges in myasthenia gravis","volume":"38","author":"Nguyen","year":"2020","journal-title":"Neurol Clin"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"102114","DOI":"10.1016\/j.pneurobio.2021.102114","article-title":"DJ-1 in neurodegenerative diseases: pathogenesis and clinical application","volume":"204","author":"Huang","year":"2021","journal-title":"Prog Neurobiol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/mus.27193","article-title":"Investigating the possible association between NLRP3 gene polymorphisms and myasthenia gravis","volume":"63","author":"Agah","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"567676","DOI":"10.3389\/fnmol.2020.567676","article-title":"Investigation of MLH1, MGMT, CDKN2A, and RASSF1A gene methylation in Thymomas from patients with myasthenia gravis","volume":"13","author":"Coppede","year":"2020","journal-title":"Front Mol Neurosci"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e200057","DOI":"10.1212\/NXI.0000000000200057","article-title":"CD59 expression in skeletal muscles and its role in myasthenia gravis","volume":"10","author":"Iwasa","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"108676","DOI":"10.1016\/j.clim.2021.108676","article-title":"Peripheral blood hsa-circRNA5333-4: a novel biomarker for myasthenia gravis","volume":"224","author":"Lv","year":"2021","journal-title":"Clin Immunol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5507\/bp.2019.009","article-title":"Upregulation of miR150-5p in generalized myasthenia gravis patients is associated with decreased serum levels of IL-17 and increased serum levels of IL-10","volume":"164","author":"Ao","year":"2020","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e13454","DOI":"10.7717\/peerj.13454","article-title":"LncRNA OIP5-AS1 modulates the proliferation and apoptosis of Jurkat cells by sponging miR-181c-5p to regulate IL-7 expression in myasthenia gravis","volume":"10","author":"Wang","year":"2022","journal-title":"PeerJ"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1508422\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T01:55:55Z","timestamp":1736214955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1508422\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":40,"alternative-id":["10.3389\/fmed.2024.1508422"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1508422","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"article-number":"1508422"}}